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The hemodynamic changes of pregnancy can have a negative impact on maternal cardiac 
health, especially in women with pre-existing cardiac disease. In the most recent Confidential 
Inquiries into Maternal Mortality in the United Kingdom, heart disease was found to be the most 
common indirect cause of maternal death during pregnancy. 
1
 Pregnancy counselling and management 
for women with heart disease is being increasing recognized as an important aspect of their overall 
cardiac care. With increasing awareness, there has been a growing body of research focused on 
pregnancy outcomes and risk stratification and new initiatives to improve clinical care. In 2011, the 
first comprehensive guidelines on pregnancy and cardiovascular disease were released by the 
European Society of Cardiology. 
2
 While our current understanding of pregnancy risk assessment and 
management has improved over the past 20 years, many questions can only be answered by 
collaborative efforts.  
 In the present issue of the European Heart Journal Roos-Hesselink and colleagues present the 
first report of their multicentre, multinational Registry On Pregnancy and Cardiac Disease (ROPAC-
registry), supported by the European Society of Cardiology. 
3
. This study is important because it 
provides a global perspective on pregnancy in women with heart disease. The study included 1321 
pregnancies in women from 28 countries; the majority of which were developed countries (86%) in 
Europe and North America. Most women from developed countries had underlying congenital heart 
disease (74%). In contrast, valvular heart disease was the predominant underlying cardiac condition 
(72%) in pregnancies reported from women in developing countries where rheumatic heart disease 
remains endemic. The study reports high rates of adverse maternal cardiac events during pregnancy 
including increased risk of maternal deaths. Hospital admission for cardiac reason complicated 15% of 
all pregnancies, primarily for treatment of heart failure. Similarly high event rates of adverse maternal 
cardiac events have been reported by other groups Figure 1. 
4, 5
. Collectively, these studies highlight 
the need to identify women at highest risk and to develop care models to improve outcomes. Because 
maternal deaths at any one centre are relative rare, large multicentre registries such as this, are 
necessary to study mortality outcomes. Although rare, maternal mortality (13/1321 pregnancies, 7 due 
to heart failure, 3 due to thromboembolic events and 3 due to non-cardiac related sepsis) was much 
more likely to occur in women with heart disease compared to the general population. While there are 
 3 
a number of risk scores for predicting adverse pregnancy outcomes in women with heart disease, this 
study externally validated the modified World Health Organization risk score as a prediction tool for 
maternal mortality, the occurrence of heart failure and foetal death. 
2, 6
  
 Cardiac disease in pregnant women will likely be increasingly encountered in medical 
practice. With advances in cardiac surgery and improved childhood survival, there is a growing 
population of young women with congenital heart disease of childbearing age. 
7, 8
 Most of these 
women, particularly those with lesions of moderate or great complexity, have residua or sequelae that 
increase their risk of cardiovascular complications during pregnancy. Rheumatic heart disease, rare in 
developed countries, remains a major health problem in developing and underdeveloped countries. 
Women with rheumatic valve lesions such as mitral stenosis tolerate pregnancy poorly.  The 
prevalence of ischemic heart disease complicating pregnancies is increasing, 
1, 9, 10
 perhaps related to 
trends in Western societies of having children later in life or the increased prevalence of 
cardiovascular risk factors in an older cohort. Further increases may occur with increasing assisted 
fertilization in older women. With this growing and evolving population, on-going education of health 
providers and patients is important. 
 Preconception counselling allows women to make informed pregnancy decisions and risk 
stratification tool can be helpful to predict pregnancy risk. A number of risk stratification tools have 
been proposed to identify those women at highest risk. 
4-6, 11
 For some cardiac lesions, there is very 
little risk of adverse cardiac events during pregnancy, no special precautions are required during 
pregnancy and women need nothing more than reassurance. In other cases, pregnancy poses a 
prohibitive risk and women need to be educated about the need to avoid pregnancy and about safe 
contraception options. Unfortunately, a number of groups have reported that women with heart 
conditions often have inaccurate knowledge of pregnancy risk or do not recall receiving pregnancy 
counselling. 
12-14
 
 Once pregnant, women identified as intermediate or high risk should receive care from a 
multidisciplinary team which includes cardiologists with expertise, high risk obstetricians, and 
obstetric anaesthetists. To date, studies have not addressed delivery of care or quality of care in this 
high risk population.  
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 The ROPAC registry is likely to have many roles. As the registry increases in size, rare 
cardiac conditions or outcomes (such as maternal, fetal or neonatal mortality) can be studied in more 
detail. The registry data can be used for validating and refining existing risk stratification scoring 
models or identify novel risk markers derived from smaller mechanistic studies. The registry data can 
help to determine and compare regional treatment strategies and outcomes. Other parameters, such as 
health care costs, could be studied. The ROPAC registry will likely be an important initiative that will 
help to improve the care of pregnant women with heart disease.  
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Figure 1. Risk of adverse cardiac events (blue) and maternal death (red) in 3 large multicentre 
studies of pregnancy outcomes in women with heart disease. 
 
 
* the CARPREG-study and the ROPAC-registry include women with congenital and acquired heart 
disease 
** the ZAHARA-study included only women with congenital heart disease 
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